Generic Urispas (Flavoxate Hcl)

Introduction

Urispas contains the antispasmodic active ingredient flavoxate hydrochloride (Flavoxate HCl) in a 200 mg oral tablet. It belongs to the class of urinary antispasmodics, agents that reduce involuntary smooth-muscle contractions of the bladder and urethra. Urispas is indicated for relief of urinary frequency, urgency, dysuria, and bladder-spasm discomfort that may accompany benign prostatic hyperplasia, urethral irritation, or postoperative urinary catheterisation. The medication is manufactured as a film-coated tablet and is supplied in 200 mg strength.

What is Urispas?

• Definition - Urispas is a prescription-only oral tablet whose sole active constituent is flavoxate HCl.
• Classification - It is classified as a urinary antispasmodic (also termed a bladder-spasm relaxant).
• Development history - Flavoxate was first synthesized in the s and received regulatory approval in several jurisdictions for the treatment of urinary-tract spasm-related symptoms. The commercial name “Urispas” is used by a specific manufacturer, but the pharmacologically active component is identical to other flavoxate products.
• Manufacturer - The product is produced by a pharmaceutical company that holds a marketing authorisation for the 200 mg tablet; specific company details are listed on the product label and in national drug registries.

How Urispas Works

Flavoxate HCl exerts its therapeutic effect primarily by stabilising the cell membranes of bladder smooth muscle. The drug reduces calcium influx through voltage-gated channels, thereby attenuating the contractile response to cholinergic (acetylcholine) stimulation. By limiting involuntary contractions, flavoxate lowers the frequency of urgency episodes and eases dysuria. The onset of action typically occurs within 30-60 minutes after oral ingestion, and the clinical effect lasts 4-6 hours, which supports a three-times-daily dosing schedule. The compound is largely excreted unchanged in the urine; renal clearance accounts for the majority of elimination, with a plasma half-life of approximately 5 hours in healthy adults.

Conditions Treated with Urispas

• Urinary frequency and urgency - In patients with benign prostatic hyperplasia (BPH) or urethral irritation, flavoxate smooths bladder contractions, reducing the sensation of needing to void repeatedly.
• Dysuria (painful urination) - By dampening spasms of the urethral sphincter, the medication lessens the pressure that contributes to pain during micturition.
• Post-catheterisation bladder spasm - After removal of a urinary catheter, transient involuntary bladder activity is common; flavoxate helps control these spasms, improving comfort and decreasing the risk of haematuria.

These indications are recognised by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for flavoxate-containing products.

Off-Label and Investigational Uses of Urispas

• Interstitial cystitis/bladder pain syndrome - Small case series have reported symptomatic improvement when flavoxate is added to multimodal therapy. Evidence remains limited, and the indication is not approved by health authorities.
• Overactive bladder (OAB) refractory to antimuscarinics - Some clinicians use flavoxate experimentally when standard agents (e.g., oxybutynin) are poorly tolerated. Clinical trials are ongoing, but results have not led to formal approval.
• Detrusor overactivity in spinal cord injury - Pilot studies suggest that flavoxate may reduce involuntary bladder contractions in neurogenic patients; safety data are still being collected.

All off-label applications should only be pursued under direct supervision of a qualified healthcare professional. The efficacy and safety for these uses have not been formally validated by regulatory bodies.

Is Urispas the Right Medication for You?

Urispas is most appropriate for adults who experience bothersome bladder-spasm symptoms that have not responded fully to lifestyle modifications (e.g., reduced caffeine, timed voiding). It is particularly useful when the underlying cause is benign prostatic enlargement, urethral irritation, or recent catheter removal.

Contraindications include:

• Known hypersensitivity to flavoxate HCl or any tablet excipients.
• Severe hepatic impairment (as hepatic metabolism contributes to clearance).
• Concurrent use of strong anticholinergic agents where additive effects could precipitate acute urinary retention.

Patients with uncontrolled narrow-angle glaucoma, prostatic obstruction requiring immediate surgical intervention, or a history of severe gastrointestinal motility disorders should discuss alternatives with their clinician.

Risks, Side Effects, and Interactions

Common

• Dry mouth
• Constipation
• Dizziness or light-headedness
• Blurred vision
• Headache

Rare

• Skin rash or pruritus
• Photosensitivity reactions
• Mild elevation of liver enzymes

Serious

• Anaphylactic or severe allergic reactions (e.g., angioedema, bronchospasm)
• Acute urinary retention (especially in patients with significant prostatic obstruction)
• Hepatic dysfunction with jaundice or hepatitis-like picture

**Drug-drug interactions

• Anticholinergics (e.g., diphenhydramine, oxybutynin): additive antimuscarinic effects may increase urinary retention risk.
• Alcohol: potentiates central nervous-system depression, leading to enhanced dizziness.
• CNS depressants (e.g., benzodiazepines, opioids): may intensify sedation and impair coordination.

Drug-food interactions

• No specific food restrictions are documented, but taking the tablet with a full glass of water improves absorption and reduces oesophageal irritation.

Patients should inform their provider of all prescription, over-the-counter, and herbal products they are using.

Use: Dosing, Missed Dose, Overdose

• Standard adult dosing - 200 mg orally three times daily after meals (approximately every 8 hours). Depending on symptom severity, clinicians may titrate to 400 mg per dose, not exceeding 120 mg per day.
• Missed dose - If a dose is forgotten and the scheduled time for the next dose is less than 4 hours away, skip the missed tablet and continue with the regular schedule. Do not double-dose to compensate.
• Overdose - Acute overdose may present with severe dizziness, confusion, hypotension, or pronounced anticholinergic toxicity (dry mouth, flushed skin, urinary retention). Seek immediate medical attention; contact the local poison-control centre. Management is primarily supportive, with monitoring of cardiovascular and respiratory status.

Practical precautions - Avoid operating heavy machinery or driving until the individual knows how flavoxate affects them. Alcohol should be limited, and patients should maintain adequate hydration to facilitate renal excretion.

FAQ

• Can Urispas be taken with other bladder-spasm medications? Flavoxate may be combined with other antispasmodics only under professional guidance, as additive effects can increase the risk of urinary retention.

• Is it safe to use Urispas during pregnancy? Animal studies have not demonstrated teratogenicity, but human data are insufficient. The medication should be avoided unless the benefit clearly outweighs potential risk, and only after discussion with a maternal-fetal specialist.

• How should Urispas be stored in hot climates? Store the tablets in a dry place away from direct sunlight and temperatures above 30 °C (86 °F). If ambient conditions are extreme, keep the container in a climate-controlled area or a refrigerator (do not freeze).

• What does the tablet look like? Urispas 200 mg tablets are film-coated, round, and typically bear a specific imprint code (e.g., “UR-200”) that varies by manufacturer. The colour is often pale blue or white, but patients should verify the appearance on the packaging.

• Are there any differences between flavoxate tablets sold in the United States and Europe? The active ingredient and therapeutic indication are the same, but excipients (binders, dyes) may differ due to regional formulation standards. Such differences rarely affect efficacy but could influence tolerability for patients with specific allergies.

• Can Urispas affect urine drug testing? Flavoxate is not a substance screened for in standard employment or forensic drug panels, and it does not cause false-positive results for commonly tested drugs.

• Is it necessary to take Urispas on an empty stomach? No. The tablet is recommended after meals to minimise gastrointestinal irritation and to improve patient comfort.

• What should I do if I experience severe constipation while taking Urispas? Increase dietary fibre, fluid intake, and consider a gentle stool softener after consulting a pharmacist. Persistent constipation warrants medical review to exclude other causes.

• Does Urispas interact with herbal supplements such as saw palmetto? Saw palmetto has mild anti-androgenic activity but no documented pharmacokinetic interaction with flavoxate. Nevertheless, patients should disclose all supplements to their healthcare provider.

• Can I travel internationally with a supply of Urispas? Yes, provided the medication is in its original labeled container, a copy of the prescription (if required) is carried, and the quantity does not exceed personal-use limits set by the destination country’s customs regulations.

Glossary

Antispasmodic

A drug that reduces involuntary smooth-muscle contractions, commonly used to alleviate bladder or gastrointestinal spasms.

Muscarinic receptor

A subtype of acetylcholine receptor found in smooth muscle, heart, and glandular tissue; blockade of these receptors reduces muscle contraction.

Bioavailability

The proportion of an orally administered dose that reaches systemic circulation unchanged; flavoxate has moderate oral bioavailability.

Half-life

The time required for the plasma concentration of a drug to decrease by 50 %; flavoxate’s half-life is about 5 hours in adults with normal renal function.

Buying Urispas from Our Online Pharmacy

Patients who encounter difficulty obtaining Urispas through local pharmacies or who seek a cost-effective alternative can purchase the medication from our online pharmacy.

• Affordable pricing - We source the generic flavoxate tablets directly from licensed manufacturers, allowing us to offer prices that are close to the original production cost.
• Verified quality - Every batch is verified for potency and purity by third-party laboratories that are accredited under international pharmacopoeial standards.
• Discreet, reliable delivery - Orders are packaged in unmarked envelopes and shipped through vetted carriers. Standard airmail typically arrives within three weeks, while an express option is available with a delivery window of about seven days.
• Privacy-focused service - As a pharmacy-broker service, we collaborate with overseas licensed pharmacies to ensure that your personal information remains confidential throughout the ordering process.

By choosing our online pharmacy, patients gain a secure, affordable pathway to obtain Urispas when conventional channels are limited or cost-prohibitive.

Disclaimer

The information presented about Urispas is intended for general educational purposes and does not substitute personalized medical advice. Treatment choices, including any off-label applications, must be made under the direct supervision of a qualified health-care professional. Readers are presumed to be responsible adults capable of evaluating health information. Our online pharmacy supplies Urispas as a generic option for individuals who may have restricted access via traditional pharmacies or insurance plans, but it is essential to consult a clinician before initiating, modifying, or discontinuing any medication.